GO
| HSI1 | 26,009.46 | 0.00 | -- |
| HSCEI1 | 8,634.34 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-08-21 16:24:46 G Sachs published a research report stating that driven by licensing fee income of about RMB5.7 billion, CSPC PHARMA (01093.HK)'s 2Q revenue surged 94% YoY, while finished drug sales grew 16% YoY, accelerating from 6% growth in 1Q. Net profit jumped 389% YoY. Excluding the licensing fee income recognized in 2Q, core earnings were estimated to remain broadly flat YoY, as growth in R&D and administrative expenses continued to outpace product sales growth. G Sachs said the development of the mRNA platform has become a key highlight. The group's therapeutic HPV mRNA vaccine has advanced to Phase II clinical trials, with encouraging early-stage data. The COVID mRNA vaccine project combined with PD-1 for solid tumors has also commenced. Management emphasized that identifying shared neoantigens through large oncology databases and AI antigen screening will enhance vaccine scalability and development efficiency. G Sachs raised its 2026-2028 earnings forecasts for CSPC PHARMA (01093.HK) by 0.2% to 1.7%, lifted the TP from HKD12.14 to HKD12.56, and maintained the Buy rating.(gc/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |